Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Stock Position in CVS Health Corporation $CVS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its stake in CVS Health Corporation (NYSE:CVS) by 3.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 295,277 shares of the pharmacy operator’s stock after selling 9,294 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in CVS Health were worth $23,433,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares in the last quarter. Capital World Investors lifted its position in CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after acquiring an additional 1,419,575 shares in the last quarter. State Street Corp lifted its position in CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after acquiring an additional 149,701 shares in the last quarter. Capital International Investors lifted its position in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after acquiring an additional 302,499 shares in the last quarter. Finally, Invesco Ltd. lifted its position in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after acquiring an additional 760,579 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce’s Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CVS. Argus upped their price objective on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. HSBC upped their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday, May 5th. Royal Bank Of Canada increased their price target on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. TD Cowen increased their price target on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, UBS Group increased their price target on CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $98.88.

CVS Health Price Performance

NYSE CVS opened at $90.97 on Monday. The business’s fifty day moving average price is $82.07 and its 200-day moving average price is $79.56. The stock has a market capitalization of $116.06 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 0.89 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the prior year, the firm earned $2.25 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.